GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Summary

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.

Timeline

Start

2018-01-22

Primary completion

2018-09-08

Completion

2022-04-28

Drugs

Indications